⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 7, 2024Journal of Nuclear MedicineOpen Access

Prognostic Performance of RECIP 1.0 Based on [¹⁸F]PSMA-1007 PET in Prostate Cancer Patients Treated with [¹⁷⁷Lu]Lu-PSMA I&T

Philipp E. Hartrampf Thomas Hüttmann Anna Katharina Seitz Hubert Kübler Sebastian E. Serfling Takahiro Higuchi Wiebke Schlötelburg Kerstin Michalski Andrei Gafita Steven P. Rowe Martin G. Pomper Andreas K. Buck Rudolf A. Werner

View Full Paper

Ask AI

Bookmark

Share

Abstract

In metastatic castration-resistant prostate cancer (mCRPC) patients treated with prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT), the recently proposed criteria for evaluating response to PSMA PET (RECIP 1.0) based on

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hartrampf et al. (2024) studied this question.

synapsesocial.com/papers/68e75433b6db6435876cc266 https://doi.org/10.2967/jnumed.123.266702

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1RECIP 1.0 Predicts Progression-Free Survival After [<sup>177</sup>Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer2024 · 28 citations
2PSMA-PET response under [177Lu]Lu-PSMA therapy: Comparison of RECIST, PERCIST, PPP, adapted PCWG4 and RECIP criteriaRetrospective Study · 2026 · 1 citations
3Evidence-Based Clinical Protocols to Monitor Efficacy of [<sup>177</sup>Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World DataPrognostic Study · 2025 · 12 citations
4SPECT Versus PET for [ <sup>177</sup> Lu]Lu-PSMA Response Assessment Using Quantitative RECIP 1.0Original Research · 2026 · 1 citations
5Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer2025 · 8 citations

More related papers

Prognostic Value of Early Follow-Up PSMA PET/CT After 2 Cycles of [ <sup>177</sup> Lu]Lu-PSMA RPT in Patients with mCRPC: Comparison with PSA Dynamics2026
[177Lu]Lu-PSMA radioligand therapy in systemic therapy-naïve metastatic hormone-sensitive prostate cancer patients: a retrospective study2026
177Lu-PSMA therapy in metastatic prostate cancer: An updated review of prognostic and predictive biomarkers2024

More from Journal of Nuclear Medicine

PSMA PET Evaluation with a Deep Learning Platform Compared with a Standard Image Viewer and HistopathologyThu,
¹⁸F-FDG PET Reveals Voxel-Based Decreases in Brain Glucose Uptake After Chemotherapy in Leukemia Patients: A Retrospective Matched-Control StudyThu,